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Background
AIDS vaccination has a pressing need for more potent vac-
cination vectors capable of eliciting strong, diversified and
long-lasting cellular immune responses against HIV. Len-
tiviral vectors have a proven efficiency not only as gene
delivery vehicles for gene therapy applications but also as
vaccination tools. This is likely due to their ability to
transduce non-dividing cells, including dendritic cells,
enabling a sustained endogenous antigen presentation
and thus the induction of high proportions of specific
cytotoxic T cells and long-lasting memory T cells.
Methods
The protective efficacy of a lentiviral vector based vaccine
was assessed in the SIVmac251/cynomolgus macaques
model.
Results
Our prime-boost vaccination strategy using lentiviral vec-
tors pseudotyped with a glycoprotein G from two non-
cross-reactive VSV serotypes elicited robust and broad cel-
lular immune responses against the vector-encoded anti-
gen, SIV GAG. Vaccination conferred strong protection
against a massive intra-rectal challenge with SIVmac251
as evidenced both by the reduction of viremia at the peak
of primo-infection (a mean of over 2 log10 fold reduc-
tion) and the full preservation of the central memory
CD4+ T cells during the acute phase. Although vaccinees
continued to display lower viremia than control
macaques during the early chronic phase, these differ-
ences were not statistically significant by day 50 post-chal-
lenge. This encouraging pilot prophylactic trial gave the
proof-of concept for the strong potential of the lentiviral
vector system for vaccination. Various optimizations were
successfully tested in mice to increase the immunogenicity
of our vaccine. An improved vaccine – with a codon-opti-
mized sequence encoding 2 viral antigens, GAG together
with NEF, under the control of a promoter devoid of asso-
ciated enhancer activity and injected via the intramuscular
route – is being evaluated in a therapeutic setting, in
viremic rhesus monkeys.
Conclusion
Gene transfer vectors derived from HIV-1 appear as prom-
ising candidates for vaccination against HIV-1 infection.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P302 doi:10.1186/1742-4690-6-S3-P302
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P302
© 2009 Beignon et al; licensee BioMed Central Ltd. 